The Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products primarily in the Middle East.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م28.58|
|52 Week High||ج.م27.50|
|52 Week Low||ج.م50.99|
|1 Month Change||-7.93%|
|3 Month Change||-23.34%|
|1 Year Change||-4.83%|
|3 Year Change||177.48%|
|5 Year Change||210.99%|
|Change since IPO||91.38%|
Recent News & Updates
|NIPH||EG Pharmaceuticals||EG Market|
Return vs Industry: NIPH underperformed the EG Pharmaceuticals industry which returned -1.9% over the past year.
Return vs Market: NIPH underperformed the EG Market which returned 12.4% over the past year.
Stable Share Price: NIPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: NIPH's weekly volatility (4%) has been stable over the past year.
About the Company
|1962||n/a||Osama Mustafa Basit||https://www.nilepharma.com.eg|
The Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products primarily in the Middle East. The company offers prescription pharmaceutical products, including tablets, capsules, dry syrups, syrups and suspensions, ointments, gels and creams, suppositories, ampoules, drops, parenteral, sachets, biotechnological products, lyophilized products, sterile antibiotic vials, lotions, shampoos, and solutions. It also provides non-prescription pharmaceutical products, such as analgesic and anti-inflammatory, antihistaminic, anthelmintic, antibacterial, antifungal, cardiovascular disorders, central nervous system and antiparkinsonism drugs, oral cavity products, respiratory system disorders, urinary tract disorders, endocrine glands disorders, gastrointestinal tract disorders, muscle relaxants, topical otic and nasal preparations, topical ophthalmological preparations, dermatological preparations, women and men healthcare products, osteoporosis, pediatrics, cosmetics, antiseptics, and immunological products, as well as vitamins and minerals.
Nile for Pharmaceuticals and Chemical Industries Fundamentals Summary
|NIPH fundamental statistics|
Is NIPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NIPH income statement (TTM)|
|Cost of Revenue||ج.م554.43m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||6.36|
|Net Profit Margin||8.53%|
How did NIPH perform over the long term?See historical performance and comparison
7.9%Current Dividend Yield
Is Nile for Pharmaceuticals and Chemical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NIPH (EGP28.58) is trading below our estimate of fair value (EGP105.38)
Significantly Below Fair Value: NIPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NIPH is good value based on its PE Ratio (4.5x) compared to the EG Pharmaceuticals industry average (5.9x).
PE vs Market: NIPH is good value based on its PE Ratio (4.5x) compared to the EG market (11.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NIPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NIPH is good value based on its PB Ratio (0.8x) compared to the EG Pharmaceuticals industry average (1.3x).
How is Nile for Pharmaceuticals and Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nile for Pharmaceuticals and Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Nile for Pharmaceuticals and Chemical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NIPH has high quality earnings.
Growing Profit Margin: NIPH's current net profit margins (8.5%) are lower than last year (11.5%).
Past Earnings Growth Analysis
Earnings Trend: NIPH's earnings have grown significantly by 46% per year over the past 5 years.
Accelerating Growth: NIPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NIPH had negative earnings growth (-31%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).
Return on Equity
High ROE: NIPH's Return on Equity (17.3%) is considered low.
How is Nile for Pharmaceuticals and Chemical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: NIPH's short term assets (EGP604.3M) exceed its short term liabilities (EGP345.0M).
Long Term Liabilities: NIPH's short term assets (EGP604.3M) exceed its long term liabilities (EGP3.8M).
Debt to Equity History and Analysis
Debt Level: NIPH's debt to equity ratio (11.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if NIPH's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NIPH's debt is well covered by operating cash flow (183.1%).
Interest Coverage: NIPH earns more interest than it pays, so coverage of interest payments is not a concern.
What is Nile for Pharmaceuticals and Chemical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: NIPH's dividend (7.87%) is higher than the bottom 25% of dividend payers in the EG market (2.63%).
High Dividend: NIPH's dividend (7.87%) is low compared to the top 25% of dividend payers in the EG market (7.87%).
Stability and Growth of Payments
Stable Dividend: NIPH has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: NIPH's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (35.4%), NIPH's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Osama Mustafa Basit
Dr. Osama Mustafa Abdul Basit serves as Chairman and Managing Director of The Nile Co. for Pharmaceuticals and Chemical Industries.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
The Nile Co. for Pharmaceuticals and Chemical Industries's employee growth, exchange listings and data sources
- Name: The Nile Co. for Pharmaceuticals and Chemical Industries
- Ticker: NIPH
- Exchange: CASE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م289.373m
- Shares outstanding: 10.13m
- Website: https://www.nilepharma.com.eg
- The Nile Co. for Pharmaceuticals and Chemical Industries
- Al-Sawah square
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:14|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.